Compare Repligen Corporation Common Stock (RGEN) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Toyota Motor Corp — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Toyota Motor Corp trades at $191 (market cap $221.69B). The key difference: Toyota Motor Corp is far larger — about 19.9× Repligen Corporation Common Stock's market cap, and Toyota Motor Corp pays a 3.32% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Toyota Motor Corp for 116 Days on average.
| RGEN | TM | |
|---|---|---|
Market Cap | $11.14B | $221.69B |
Volume | 1,259,263 | 298,766 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $248.29 |
52-Week Low | $102.87 | $166.50 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $11.02B | $414.72B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Toyota Motor trades at $188.60, up 2.1% with bearish technical signals but strong fundamentals. The stock shows attractive valuation with P/E of 8.5 and P/S of 0.74, supported by consistent earnings beats. Recent news highlights growing U.S. market share and electrification progress, though China sales remain a concern. Cash flow trends show recovery from 2025's negative position to projected $2.25T positive in 2026.
Toyota presents a value opportunity with solid profitability and market positioning, though technical weakness and China headwinds warrant caution. The 37.5% buy rating from analysts reflects divided sentiment despite strong fundamentals. Key catalysts include electrification expansion and U.S. market gains, while risks involve production disruptions and competitive pressures in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
